Skip to main content
Article thumbnail
Location of Repository

Substance Use Disorders in Schizophrenia—Clinical Implications of Comorbidity

By Nora D. Volkow

Abstract

Nearly half of the people suffering from schizophrenia also present with a lifetime history of substance use disorders (SUD), a rate that is much higher than the one seen among unaffected individuals. This phenomenon suggests that the factors influencing SUD risk in schizophrenia may be more numerous and/or complex than those modulating SUD risk in the general population. It is critically important to address this comorbidity because SUD in schizophrenic patients is associated with poorer clinical outcomes and contributes significantly to their morbidity and mortality

Topics: Editorial
Publisher: Oxford University Press
OAI identifier: oai:pubmedcentral.nih.gov:2669586
Provided by: PubMed Central

Suggested articles

Citations

  1. (2005). A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr Res.
  2. (2001). A neurobiological basis for substance abuse comorbidity in schizophrenia. Biol Psychiatry.
  3. Behavioral interventions for dual-diagnosis patients.
  4. Cannabis use and misuse prevalence among people with psychosis.
  5. (2003). Characteristics of subgroups of individuals with psychotic illness and a comorbid substance use disorder. Psychiatr Serv.
  6. (2001). Cognitive effects of nicotine. Biol Psychiatry.
  7. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study.
  8. (1998). Diagnosis and management of substance use disorders among inpatients with schizophrenia. Psychiatr Serv.
  9. Double jeopardy: schizophrenia and substance use.
  10. (2009). Further evidence of differences in substance use and dependence between Australia and the United States. Drug Alcohol Depend.
  11. (2002). Initiation of daily smoking and nicotine dependence in schizophrenia and mood disorders. Schizophr Res.
  12. (2005). Ionotropic and metabotropic glutamate receptor structure and pharmacology. Psychopharmacology (Berl).
  13. Molecular genetics of addiction and related heritable phenotypes: genome-wide association approaches identify ‘‘connectivity constellation’’ and drug target genes with pleiotropic effects.
  14. (2005). Negative symptoms and specific cognitive impairments as combined targets for improved functional outcome within cognitive remediation therapy. Schizophr Bull.
  15. (2004). Nicotine dependence and psychiatric disorders in the United States: results from the national epidemiologic survey on alcohol and related conditions. Arch Gen Psychiatry.
  16. (1977). Non-random relation between drugs of abuse and psychiatric diagnosis. J Psychiatr Res.
  17. (1998). Patterns of current and lifetime substance use in schizophrenia. Schizophr Bull.
  18. Profound decreases in dopamine release in striatum in detoxified alcoholics: possible orbitofrontal involvement.
  19. (2008). Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia. Arch Gen Psychiatry.
  20. (1997). Schizophrenia: a neural diathesisstress model. Psychol Rev.
  21. Serious mental illness and tobacco addiction: a model program to address this common but neglected issue.
  22. Smoking and schizophrenia: epidemiological and clinical features.
  23. (2003). Source and Accuracy Statement for
  24. Substance use in a population-based clinic sample of people with first-episode psychosis.
  25. (1996). Substance use: a powerful predictor of relapse in schizophrenia. Schizophr Res.
  26. (2005). The associations between substance use disorders, schizophreniaspectrum disorders, and Axis IV psychosocial problems. Soc Psychiatry Psychiatr Epidemiol.
  27. The element of surprise.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.